Coptisine exerts anti‐tumour effects in triple‐negative breast cancer by targeting mitochondrial complex I
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16489 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Yunfu Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Berberine, Electron Transport Complex I, Mitochondria. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Science and Technology Development Fund, Hong Kong and Macao Joint Research and Development Fund of Wuyi University.
Abstract (Originalsprache)
Background and Purpose Triple‐negative breast cancer (TNBC) has a poor prognosis due to limited therapeutic options. Recent studies have shown that TNBC is highly dependent on mitochondrial oxidative phosphorylation. The aim of this study was to investigate the potential of coptisine, a novel compound that inhibits the complex I of the mitochondrial electron transport chain (ETC), as a treatment for TNBC. Experimental Approach In this study, mitochondrial metabolism in TNBC was analysed by bioinformatics. In vitro and in vivo experiments (in mice) were conducted to evaluate the potential of coptisine as an ETC complex I‐targeting therapeutic agent and to investigate the molecular mechanisms underlying coptisine‐induced mitochondrial dysfunction. The therapeutic effect of coptisine was assessed in TNBC cells and xenograft mouse model. Key Results We demonstrated that mitochondrial ETC I was responsible for this metabolic vulnerability in TNBC. Furthermore, a naturally occurring compound, coptisine, exhibited specific inhibitory activity against this complex I. Treatment with coptisine significantly inhibited mitochondrial functions, reprogrammed cellular metabolism, induced apoptosis and ultimately inhibited the proliferation of TNBC cells. Additionally, coptisine administration induced prominent growth inhibition that was dependent on the presence of a functional complex I in xenograft mouse models. Conclusion and Implications Altogether, these findings suggest the promising potential of coptisine as a potent ETC complex I inhibitor to target the metabolic vulnerability of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
- Department of Pediatrics, Affiliated Hospital of Southwest Medical University, Birth Defects Clinical Medical Research Center of Sichuan Province, Luzhou, China.
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China.
Förderung
- Science and Technology Development Fund
- Hong Kong and Macao Joint Research and Development Fund of Wuyi University
Zitieren
APA
Shen, Y., Yang, Y., Wang, Z., Lin, W., Feng, N., Shi, M., Liu, J., & Ma, W. (2024). Coptisine exerts anti‐tumour effects in triple‐negative breast cancer by targeting mitochondrial complex I. British Journal of Pharmacology. https://doi.org/10.1111/bph.16489
Vancouver
Shen Y, Yang Y, Wang Z, Lin W, Feng N, Shi M, et al. Coptisine exerts anti‐tumour effects in triple‐negative breast cancer by targeting mitochondrial complex I. British Journal of Pharmacology. 2024. doi:10.1111/bph.16489
BibTeX
@article{Shen2024,
author = {Shen, Yunfu and Yang, You and Wang, Zi and Lin, Wanjun and Feng, Na and Shi, Meina and Liu, Jiachen and Ma, Wenzhe},
title = {Coptisine exerts anti‐tumour effects in triple‐negative breast cancer by targeting mitochondrial complex I},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16489}
}
EUVIMED